Altimmune (ALT) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.49% |
| Dec 31, 2025 | -4.83% |
| Sep 30, 2025 | -7.99% |
| Jun 30, 2025 | -17.94% |
| Mar 31, 2025 | -35.38% |
| Dec 31, 2024 | 0.14% |
| Sep 30, 2024 | -28.87% |
| Jun 30, 2024 | -31.63% |
| Mar 31, 2024 | -31.92% |
| Dec 31, 2023 | -31.04% |
| Sep 30, 2023 | -61.02% |
| Jun 30, 2023 | -97.28% |
| Mar 31, 2023 | -70.14% |
| Dec 31, 2022 | -47.66% |
| Sep 30, 2022 | -49.31% |
| Jun 30, 2022 | -74.35% |
| Mar 31, 2022 | -130.99% |
| Dec 31, 2021 | -22.26% |
| Sep 30, 2021 | -8.02% |
| Jun 30, 2021 | -56.57% |
| Mar 31, 2021 | -73.92% |
| Dec 31, 2020 | -115.57% |
| Sep 30, 2020 | -52.53% |
| Jun 30, 2020 | -34.24% |
| Mar 31, 2020 | -15.95% |
| Dec 31, 2019 | -14.86% |
| Sep 30, 2019 | -14.87% |
| Jun 30, 2019 | -29.95% |
| Mar 31, 2019 | -36.73% |
| Dec 31, 2018 | -27.26% |
| Sep 30, 2018 | 12.81% |
| Jun 30, 2018 | 19.45% |
| Mar 31, 2018 | 2.01% |
| Dec 31, 2017 | -4.51% |
| Sep 30, 2017 | -3.14% |
| Jun 30, 2017 | 6.45% |
| Mar 31, 2017 | 29.12% |
| Dec 31, 2016 | -44.05% |
| Sep 30, 2016 | -67.19% |
| Jun 30, 2016 | -10.34% |
| Mar 31, 2016 | -7.96% |
| Dec 31, 2015 | 17.01% |
| Sep 30, 2015 | -44.95% |
| Jun 30, 2015 | -93.31% |